ArticleBMC geriatrics2025
Examining the cost burden of dietary supplements in older adults: an analysis from the AAA longroad study.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of dietary supplements (DS) has steadily increased over the last several decades, particularly among older adults, contributing to the growth of the multibillion-dollar DS industry. The cost of prescription medication is a known contributor to medication nonadherence, yet the cost burden of DS among older adults is not well understood.
methodsUsing medication data from the 5-year multicenter longitudinal cohort AAA LongROAD study of older adults who drive, DS were identified and categorized. Cost estimates were based on prices obtained from a popular online marketplace, using dosing and frequency recommendations from the National Institutes of Health Office of Dietary Supplements database. ANOVA was used to explore associations between demographics and DS cost burden.
resultsOf the 2,990 participants at baseline, 2068 (69%) followed up through year 5. The number of DS users ranged from 70.4 to 82.7% of the participants from baseline to year 5. Among the 160 supplement formulations identified, 142 (88%) had price data and were included in the analysis. The mean estimated cost of individual supplements ranged from $0.73 to $49.59 per month. The mean monthly cost burden for all older adult participants ranged from $10.23 (SD 14.74) at baseline to $13.14 (SD 16.93) in year 3, with a mean annual cost burden of $142 per participant across all years. The mean monthly cost burden for DS users only ranged from $14.56 (SD 15.59) at baseline, to $16.45 (SD 17.45) in year 3, with a mean annual cost burden of $186 per DS user across all years. Increased spending was associated with female gender, older age, higher income, not working, and being White non-Hispanic.
conclusionThe use of DS is common among older adults. Using conservative estimates of monthly cost, the spending of older adults on DS is high. The real-world impact of DS costs on older adults, such as the impact on the affordability of prescription medication, is a key point for future research. CLINICAL TRIAL NUMBER: Not applicable.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.